REG - Sareum Holdings PLC - Exercise of Warrants

Sareum HoldingsAnnouncement

24/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250424:nRSX0174Ga&default-theme=true

RNS Number : 0174G  Sareum Holdings PLC  24 April 2025

Sareum Holdings PLC

("Sareum" or the "Company")

Exercise of Warrants

Cambridge, UK, 24 April 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, announces that it has received
notices to exercise certain warrants to subscribe for a total of 924,242 new
ordinary shares in the capital of the Company at a price of 12.5 pence per
ordinary share ("New Ordinary Shares") for a total consideration to the
Company of £115,530.25.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange plc for the admission
of the 924,242 New Ordinary Shares to trading on AIM ("Admission"). It is
expected that Admission will occur at 8.00 a.m. (London time) on or around 29
April 2025. The New Ordinary Shares will rank pari passu with the existing
ordinary shares.

Immediately following Admission, the total number of ordinary shares in issue
will be 134,411,893 and the total number of voting rights will therefore be
134,411,893, and this figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure and Transparency Rules.

- ENDS-

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chairman         01223 497700

                                            ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Oberon Capital (Joint Broker)

 Mike Seabrook / Nick Lovering              020 3179 5300

 Hybridan LLP (Joint Broker)

 Claire Noyce                               020 3764 2341

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi             020 3709 5700

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

The Company has recently acquired the license for SRA737, a clinical-stage
Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA
damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEASLLALKSEEA